Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
The average of the dividend yield over the last 60 months.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!